One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The essential role of docosahexaenoic acid and its derivatives for retinal integrity
Daniëlle Swinkels, Myriam Baes
doi : 10.1016/j.pharmthera.2023.108440
Volume 247, July 2023, 108440
Corrigendum to “Game of clones: Battles in the field of carcinogenesis� [Pharmacology & Therapeutics, volume 237, Pages 108–251]
Zahraa Rahal, Ansam Sinjab, Ignacio I. Wistuba, Humam Kadara
doi : 10.1016/j.pharmthera.2023.108446
Volume 247, July 2023, 108446
Pathogenic helper T cells as the novel therapeutic targets for immune-mediated intractable diseases
Atsushi Onodera a,b,1 , Kota Kokubo a,1 , Mikiko Okano a , Miki Onoue a , Masahiro Kiuchi a , Chiaki Iwamura a , Tomohisa Iinuma c , Motoko Y. Kimura d,e , Nobuyuki Ebihara f , Toyoyuki Hanazawa c , Toshinori Nakayama a,g,?, Kiyoshi Hirahara
doi : 10.1016/j.pharmthera.2023.108445
Volume 247, July 2023, 108445
Bacterial extracellular vesicles and their interplay with the immune system
Etienne Doré a,b , Eric Boilard
doi : 10.1016/j.pharmthera.2023.108443
Volume 247, July 2023, 108443
Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target
Katharina Jandl a,b,?, Nemanja Radic c , Katarina Zeder d,e , Gabor Kovacs b,d , Grazyna Kwapiszewska
doi : 10.1016/j.pharmthera.2023.108438
Volume 247, July 2023, 108438
Targeting mitochondrial function in macrophages: A novel treatment strategy for atherosclerotic cardiovascular disease?
Pierre - Hadrien Becker a,b,?, Patrice Thérond a,b , Pauline Gaignard
doi : 10.1016/j.pharmthera.2023.108441
Volume 247, July 2023, 108441
Acidosis-related pain and its receptors as targets for chronic pain
Chih-Hsien Hung a,b,1 , Yin Chin c,1 , Yi-On Fong a,b , Cheng-Han Lee d , Der-Sheng Han e , Jiann-Her Lin f,g , Wei-Hsin Sun c,??, Chih-Cheng Chen
doi : 10.1016/j.pharmthera.2023.108444
Volume 247, July 2023, 108444
Prolactin and pain of endometriosis
Grace J. Lee, Frank Porreca, Edita Navratilova
doi : 10.1016/j.pharmthera.2023.108435
Volume 247, July 2023, 108435
Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?
Thomas H. Thatcher a , Margaret A.T. Freeberg a , Yu Par Aung Myo b , Patricia J. Sime
doi : 10.1016/j.pharmthera.2023.108460
Volume 247, July 2023, 108460
Targeting tumor endothelial cells with methyltransferase inhibitors: Mechanisms of action and the potential of combination therapy
Shu Zhou a,1 , Hailong Ou a,1 , Yatao Wu a , Dan Qi d , Xiaming Pei c , Xiaohui Yu c , Xiaoxiao Hu a,b,?, Erxi Wu
doi : 10.1016/j.pharmthera.2023.108434
Volume 247, July 2023, 108434
Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
Matthieu Delaye a,b , Adrien Rousseau c , Léah Mailly-Giacchetti d , Sandra Assoun e , Harry Sokol f,g,h , Cindy Neuzillet
doi : 10.1016/j.pharmthera.2023.108442
Volume 247, July 2023, 108442
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis
Magnus B?ck
doi : 10.1016/j.pharmthera.2023.108439
Volume 247, July 2023, 108439
Integrins in cancer: Emerging mechanisms and therapeutic opportunities
Fangfang Liu a,b,1 , Qiong Wu b,c,1 , Zigang Dong a,b,c,d,e,?, Kangdong Liu
doi : 10.1016/j.pharmthera.2023.108458
Volume 247, July 2023, 108458
Resolution of inflammation in oral diseases
Eiba G. Eltay a,c , Thomas Van Dyke
doi : 10.1016/j.pharmthera.2023.108453
Volume 247, July 2023, 108453
